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Tamoxifen is an anti-estrogen drug used in treatment of Estrogen Receptor (ER) positive
breast cancer. Effects and side effects of tamoxifen is the sum of tamoxifen and all its metabo-
lites. 4-Hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen (4OHNDtam,
endoxifen) both have ER affinity exceeding that of the parent drug tamoxifen. 4OHNDtam is
considered the main active metabolite of tamoxifen. Ndesmethyltamoxifen (NDtam) is the
major tamoxifen metabolite. It has low affinity to the ER and is not believed to influence tumor
growth. However, NDtammight mediate adverse effects of tamoxifen treatment. In this study
we investigated the gene regulatory effects of the three metabolites of tamoxifen in MCF-7
breast cancer cells.
Material and Methods
Using concentrations that mimic the clinical situation we examined effects of 4OHtam,
4OHNDtam and NDtam on global gene expression in 17β-estradiol (E2) treated MCF-7
cells. Transcriptomic responses were assessed by correspondence analysis, differential
expression, gene ontology analysis and quantitative real time PCR (Q-rt-PCR). E2 depriva-
tion and knockdown of Steroid Receptor Coactivator-3 (SRC-3)/Amplified in Breast Cancer
1 (AIB1) mRNA in MCF-7 cells were performed to further characterize specific effects on
gene expression.
Results
4OHNDtam and 4OHtam causedmajor changes in gene expression compared to treatment
with E2 alone, with a stronger effect of 4OHNDtam. NDtam had nearly no effect on the global
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gene expression profile. Treatment of MCF-7 cells with 4OHNDtam led to a strong down-reg-
ulation of the CytoKeratin 6 isoforms (KRT6A, KRT6B and KRT6C). The CytoKeratin 6
mRNAs were also down-regulated in MCF-7 cells after E2 deprivation and after SRC-3/
AIB1 knockdown.
Conclusion
Using concentrations that mimic the clinical situation we report global gene expression
changes that were most pronounced with 4OHNDtam and minimal with NDtam. Genes
encoding CytoKeratin 6, were highly down-regulated by 4OHNDtam, as well as after E2
deprivation and knockdown of SRC-3/AIB1, indicating an estrogen receptor-dependent
regulation.
Introduction
The Selective Estrogen Receptor Modulator (SERM) tamoxifen is used in breast cancer treat-
ment and prevention. It may act as a full estrogen agonist, partial agonist or antagonist depend-
ing on the dose, species, or target organ [1]. Tamoxifen is regarded as a pro-drug since two of
its metabolites, 4-hydroxytamoxifen (4OHtam) and 4-hydroxy-N-demethyltamoxifen
(4OHNDtam, endoxifen), both have Estrogen Receptor (ER) affinity markedly exceeding that
of tamoxifen itself [2–4]. 4OHNDtam is considered the main active metabolite of tamoxifen
since it has 100-fold higher affinity for the ER than tamoxifen and its serum levels are 10-fold
higher than that of 4OHtam [5–9]. During steady state tamoxifen treatment the concentrations
of 4OHtam, 4OHNDtam and Ndesmethyltamoxifen (NDtam) are roughly present in serum in
concentrations 5, 50 and 150% respectively compared to that of tamoxifen [10–12]. However
in the clinical situation, these concentrations vary up to tenfold between patients using an iden-
tical daily dose, furthermore the concentrations increase by increasing age [9, 13].
Properties of tamoxifen metabolites may be studied in the ER positive human breast cancer
cell line MCF-7. The majority of in vitro studies on effects of tamoxifen are using 4OHtam as
single drug, whereas studies including 4OHNDtam as single drug are used only in few in vitro
studies. Lim et al observed that 4OHNDtam and 4OHtam have similar effects on the global ex-
pression pattern in MCF-7 cells, especially on the estrogen-regulated genes [14]. Hawse et al
also studying global gene expression in MCF-7 cells observed that 4OHNDtam molecular
mechanism of action was concentration dependent and different than that of other anti-estro-
gens [15]. High but not low concentrations of 4OHNDtam resulted in induction of cell cycle
arrest and markers of apoptosis [15]. Recently, effects of 4OHNDtam as single drug have been
examined in animal studies [16, 17] and at present clinical studies using 4OHNDtam as single
drug are underway [15]. NDtam is the major tamoxifen metabolite in serum, but due to a low
affinity to the ER NDtam is believed not to influence tumor growth and little attention has
been drawn to the compound.
The effects and side effects represent a summary of effects of tamoxifen and all its metabo-
lites. In two earlier studies where the hydroxylated metabolites were not measured, it was ob-
served that the proportion of tamoxifen and its demethylated metabolites NDtam and N-
desdimethyltamoxifen (NDDtam) in serum was higher in patients with toxicity versus those
not experiencing toxicity [18, 19]. More recent studies report that women with higher
4OHNDtam levels are more likely to report side effects [13, 20].
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In the present explorative study we examined effects of the major demethylated tamoxifen
metabolite NDtam and the hydroxylated potent metabolites 4OHtam and 4OHNDtam on
global gene expression in MCF-7 cells using concentrations that are representative for the clini-
cal situation [9, 21]. We also studied differences in effects between 4OHtam and 4OHNDtam
which may influence tumor growth and searched for genes that had the most extensive changes
in gene expression profile.
Materials and Methods
Cell culture
Michigan Cancer Foundation-7 (MCF-7) human breast adenocarcinoma cells [22] were grown
at 37°C under 5% CO2, in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum, 1% (vol/vol) penicillin/streptomycin solution and 4.5 g/liter glucose. The
MCF-7 cell medium also contained 1 μM insulin. The MCF-7 cell line is a commercial cell line
in which no ethical approval is required for experiments.
Cell treatments
Treatment of MCF-7 cells with tamoxifen metabolites. The cells were preconditioned in
phenol red-free DMEM (Invitrogen, Carlsbad, CA) containing charcoal-stripped fetal bovine
serum (HycloneTM, Thermo Fischer Scientific, MA, USA) and the above supplements, for 2
days. The cells were seeded in six-well plates at a density of 300,000 cells/ml and then treated
with 10nM E2 alone or in combination with 4OHNDtam, 4OHtam or NDtam (Table 1) for
three days. E2 and 4OHtam (>70% Z isomer) were purchased from Sigma-Aldrich (Steinheim,
Germany) and 4OHNDtam (Z/E isomers 1/1) from Sintef Materials and Chemistry (Oslo, Nor-
way). NDtam was a gift from Imperial Chemical Industries, PLC Pharmaceutical divisions (Mac-
clesfield, UK). Cells were harvested after 3 days of incubation for the microarray analysis. The
growth medium from the incubated cell cultures was collected and the concentrations of tamoxi-
fen and its metabolites determined by High Pressure Liquid Chromatography (HPLC)—Tandem
Mass Spectrometry (MS/MS) [8, 23].
Estrogen deprivation and knockdown of SRC-3 in MCF-7 cells. MCF-7 cells were
grown in alpha MEM (Lonza, Belgium) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, 100 units penicillin, 100 μg streptomycin and 1 μM insulin for one day
and then grown in phenol red-free Alpha MEM supplemented with 5% charcoal-stripped FBS




Day 0 1000 100 1000
Measured
Day 1 939 72,6 609
Day 2 158 16 64,9
Day 3 119 (93–133) 6.0 (4.0–7.7) 36.6 (26.4–54.4)
Concentrations determined by High Pressure Liquid Chromatography (HPLC)—Tandem Mass Spectrometry (MS/MS). Three measurements performed at
day 3. One measurement performed at day 1 and 2.
doi:10.1371/journal.pone.0122339.t001
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for 3 days. MCF-7 cells grown for 3 days with the addition of 10 nM 17β-estradiol (Sigma)
were used as control.
Short Hairpin RNA (shRNA) lentiviral transduction was used to generate MCF-7 cells con-
taining stably integrated shRNA SRC-3/AIB1 mRNA as previously described [24]. 68% reduc-
tion in SRC-3/AIB1 mRNA expression was obtained after KD of SRC-3 (SRC-3 shRNA)
compared to the control shRNA.
Homogenization and RNA extraction
Lysates from cell samples were harvested in PBS and RNA was extracted using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. Samples
were treated with the RNase-Free DNase Set (Qiagen). Amount and quality of the extracted
RNA were measured by the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies,
ThermoScientific, Waltham, MA, USA) and the Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA).
Illumina iScan system
250 ng of RNA from the cell samples treated with E2, NDtam, 4OHtam and 4OHNDtam were
biotin-labeled and amplified using the Illumina TotalPrep RNA amplification kit (Ambion,
Austin, TX, USA) and the Eppendorf Mastercycler (Eppendorf Hamburg, Germany). This pro-
cedure involves RNA being reversely transcribed, amplified and biotin-16-UTP-labeled. The
biotin-labeled cRNA was thereafter quality and quantity controlled using the Agilent 2100
Bioanalyzer and the NanoDrop ND-1000 spectrophotometer. 1500 ng of cRNA was hybridized
to the humanWG-6 v.3.0 expression BeadChip (Illumina, San Diego, CA, USA) and the fluo-
rescence of the biotin-labeled cRNA was detected using the Illumina iScan.
Microarray data extraction and analysis
Quality control and preprocessing. After scanning in the iScan reader the microarray
raw data was imported into GenomeStudio software (Illumina) which removed control probes
and produced a text file that contained the signal and detection p-values per probe for all sam-
ples. This text file was further imported into J-Express 2009 (MolMine AS, Norway) where sig-
nal intensity values were quantile normalized and logarithmically transformed (base 2) [25].
Quantile normalization removes obscuring variations that arise from differences in the prepa-
ration of the microarray samples. A Correspondence Analysis (CA) and hierarchical clustering
with Pearson Correlation as a distance measure were performed to visualize the differential ex-
pression between the four differently treated groups and analyze global trends in the data [26].
In adherence to the standards of the Microarray Gene Expression Data Society (mged) the
microarray data is publicly available at ArrayExpress under the title “Tamoxifen treatment of
MCF-7 breast cancer cells” and accession number (E-MTAB-2729).
Analyses of differentially expressed genes. To search for differentially expressed genes in
MCF-7 breast cancer cells treated with E2, NDtam, 4OHtam or 4OHNDtam a Significance
Analysis of Microarrays (SAM) [27] was applied. The SAM analysis calculates the significance
of the gene expression based on the deviation between the actual signal intensity and the signal
intensity expected by chance. To obtain manageable datasets, differentially expressed genes
were defined by q-value = 0. A rank product analysis was set up to examine if there were genes
that were more regulated by one metabolite than the other. By using this non-parametric statis-
tical method it was possible to rank the genes according to fold change and compare several
rank product lists against each other. The analysis was performed using J-express (Molmine)
and Excel (Microsoft).
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To analyze which Gene Ontology (GO) functional groups the differentially expressed genes
belonged to Protein ANalysis THrough Evolutionary Relationships (PANHTER) (dated, 15.
February, 2012) [28] was applied. PANTHER identifies which functional groups are over-rep-
resented among a selection of genes and expresses the degree of over-representation with p-val-
ues (binomal statistics). The integrated gene ontology analysis in J-Express 2012 (Molmline)
software was used to validate the findings from PANTHER. Gene lists used for PANTHER
were compared to the entire gene list from the microarray and an over-representation analysis
was performed.
Quantitative-real time-PCR
1 μg or 350 ng RNA per reaction was transcribed to cDNA using the Transcriptor First Strand
cDNA Synthesis Kit (Roche Diagnostics, GmbH, Mannheim, Germany) and further quantified
using the LightCycler480 Probes Master kit (Roche) and the LightCycler480 rapid thermal cy-
cler system (Roche). Each gene was quantified relative to reference genes TATA-binding pro-
tein (TBP), glucose-6-phosphate-1-dehydrogenase (G6PD) or peptidylprolyl isomerase A /
Cyclophilin A (PPIA) to correct for variations occurring within samples and during sample
preparations. The quantification of the genes was performed using specific Universal ProbeLi-
brary (UPL) probes and target-specific primers, designed at Universal ProbeLibrary (UPL)
Assay Design Center (Roche, Applied Science), software version 2.45 (S1 Table). The relative
quantification of the genes was performed according to manufactures protocol (Roche Applied
Science).
Results
To elucidate the gene regulative roles of the three tamoxifen metabolites 4OHtam, 4OHNDtam
and NDtam in breast cancer, we performed a microarray analysis on MCF-7 cells. The MCF-7
cells were treated with the respective tamoxifen metabolites and E2 for three days with concen-
trations intended to mimic physiological concentrations (Table 1). We used the concentration
levels found in tissues which are approximately 10 times higher than the concentrations found
in serum [29]. Although the inter-individual serum concentrations of tamoxifen and its main
metabolites vary tenfold and increase by age [9], the ratio between 4OHNDtam/4OHtam is
usually 10/1 in the individual patient [9, 21]. Therefore, we used a concentration of 4OHND-
tam ten times higher than that of 4OHtam. To analyze the differential expression on a global
level between the four compounds (E2, 4OHtam, NDtam and 4OHNDtam), a Correspondence
Analysis (CA) was performed (Fig 1). The CA, displaying global gene expression in a two-di-
mensional plot, showed that the samples treated with 4OHtam and 4OHNDtam were clearly
separated from control (E2). 4OHtam and 4OHNDtam shifted gene expression in the same di-
rection, but the shift was greater for 4OHNDtam (Fig 1). The samples treated with NDtam
were clustered closely with the E2 control suggesting limited effect on gene expression in MCF-
7 cells.
To further visualize gene expression trends in our dataset we performed a self-organizing
map analysis. This clustering analysis was performed on high level mean normalized expres-
sion values for genes with a significant expression value (q-value = 0) when comparing treat-
ment to control (E2). The results showed a stepwise regulation between 4OHtam and
4OHNDtam, where 4OHNDtam resulted in the most differential expression (Fig 2).
A Significance Analysis of Microarray (SAM) identified the differentially expressed genes
for each metabolite compared to control (E2). Only six NDtam-regulated genes met the
1.5-fold change and q-value = 0 cut-off for differential expression, but half of these genes over-
lapped with one or both of the other treatment groups (Fig 3). Of the 251 genes regulated by
Cytokeratin 6 Is Down-Regulated by 4OHNDtam (Endoxifen) in MCF-7 Cells
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4OHNDtam and 115 regulated by 4OHtam, there were 66 overlapping genes, i.e. 57% of the
4OHtam-regulated genes were also regulated in the same direction at least 1.5-fold by
4OHNDtam. Differential expression observed in the microarray (S2–S5 Tables) was confirmed
using Q-rt-PCR on a selection of genes with high differential expression (Table 2).
In the gene list for 4OHNDtam treated cells, the cytokeratin 6 (KRT6) genes were strikingly
down-regulated compared to control (E2). KRT6A was down-regulated 9.1-fold compared to
control while KRT6B and KRT6C were down-regulated 3.3- and 4.1-fold, respectively (S3
Table). The strong down-regulation of these genes was confirmed by Q-rt-PCR (Table 2). To
further explore whether the down-regulation of the KRT6s were regulated through estrogen re-
ceptor signaling we did two separate Q-rt-PCR analyses. Firstly, we cultured the cells in absence
of E2 for 3 days and examined the expression levels of the three KRT6s by Q-rt-PCR (Fig 4).
Estrogen deprivation of the MCF-7 cells for 3 days nearly abolished the mRNA expression
of KRT6A and B. Estrogen deprivation also down-regulated the KRT6C mRNA levels, but to a
less extent than KRT6A and B. Secondly, we knocked down the ligand-dependent ER-coactiva-
tor Steroid Receptor Coactivator 3 (SRC-3), also known as Amplified in Breast Cancer 1 (AIB1)
Fig 1. Correspondence analysis showing projection of MCF-7 cell samples treated with E2, NDtam,
4OHtam and 4OHNDtam. The x-axis displays the first principle component (variance: 8.01%) and y-axis
displays the second principle component (variance: 6.959%). The MCF-7 cell samples; MCF-7 treated with
only E2 (blank circle), MCF-7 treated with E2 and NDtam (blank triangle), MCF-7 treated with E2 and 4OHtam
(black square), and MCF-7 treated with E2 and 4OHNDtam (black circle).
doi:10.1371/journal.pone.0122339.g001
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Fig 2. Self-organizingmaps displaying stepwise regulation between 4OHNDtam and 4OHtam. Self-
organizing map displaying the high level mean normalized log2 transformed signal intensities (y-axis) across
different treatments (x-axis). Each treatment has 5 parallel samples (x-axis). Figure A displays a clustering of
Cytokeratin 6 Is Down-Regulated by 4OHNDtam (Endoxifen) in MCF-7 Cells
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(Fig 5). SRC-3/AIB1 knockdown also repressed the expression of all three KRT6s. Based on
these data, we conclude that the KRT6s are positively regulated by E2.
To inform on functions of the differentially expressed genes after treatment with the three
different metabolites (fold change 1.5, q-val = 0) we performed the Gene Ontology (GO)
analysis with PANTHER. Differentially expressed genes after treatment with 4OHNDtam and
4OHtam were largely enriched in the same GO categories (Fig 6). However, the categories are
more over-represented after treatment with 4OHNDtam compared to 4OHtam. This may re-
flect the fact that there are more genes that met the cut of criteria for the clinical applicable con-
centration (1000 ng/mL) of 4OHNDtam (82", 142#) in contrast to the lower concentration
(100 ng/mL) of 4OHtam (53", 58#). NDtam on the other hand, has no representation in PAN-
THER because the fold change of 1.5 only resulted in 3 differentially expressed genes despite
having a concentration of 1000 ng/mL. Studying specific categories in PANTHER we observed
genes belonging to the category cell cycle to be down-regulated after both treatments (4OHtam
and 4OHNDtam), while genes involved in cell adhesion were up-regulated. In addition, treat-
ment of MCF-7 cells with 4OHtam resulted in a clear down-regulation of genes involved in ap-
optosis, while treatment with 4OHNDtam resulted in both up- and down-regulation of the
apoptosis related genes. Of particular note, only 4OHNDtam showed a significant effect on
genes related to antigen processing and presentation (up-regulation). To validate our findings
in the PANTHER analysis we performed an alternative GO over-representation analysis using
down-regulated genes in a stepwise regulation where 4OHNDtam is the strongest down-regulated. Figure B
shows a clustering of up-regulated genes regulated in a stepwise regulation with 4OHNDtam being the most
up-regulated.
doi:10.1371/journal.pone.0122339.g002
Fig 3. Venn diagram showing genes uniquely regulated and regulated in the same direction after
treatment with tamoxifen metabolites.Genes included have a fold change |1.5| and q-value = 0 when
comparing tamoxifen metabolites to E2. The numbers in the overlapping circles shows the number of genes
regulated in the same direction by different treatments.
doi:10.1371/journal.pone.0122339.g003
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the integrated GO analysis software in J-Express 2012. This analysis resulted in predominantly
the same over-represented categories as in PANTHER (S6 Table).
Table 2. Validation of microarray fold change values using Q-rt-PCR.
Target gene NDtam 4OHtam 4OHNDtam
KRT6A Microarray 0.99 0.93 0.73
Q-rt-PCR 0.84 (0.52–1.07) 0.49 (0.23–1.06) 0.06 (0.05–0.08)
KRT6C Microarray 0.99 0.94 0.78
Q-rt-PCR 1.08 (0.7–1.32) 0.69 (0.24–1.40) 0.11 (0.05–0.12)
CXCR4 tv2 Microarray 0.9 0.694 0.63
Q-rt-PCR 0.68 (0.51–0.90) 0.45 (0.37–0.54) 0.35 (0.27–0.47)
SERPINA3 Microarray 0.73 0.3 0.12
Q-rt-PCR 0.64 (0.58–0.69) 0.21 (0.18–0.24) 0.07 (0.05–0.08)
GPER TV4 Microarray 0.92 0.39 0.27
Q-rt-PCR 0.85 (0.76–0.94) 0.34 (0.26–0.43) 0.24 (0.15–0.35)
CTGF Microarray 1.14 1.1 2.24
Q-rt-PCR 1.05 (0.82–1.28) 1.54 (1.26–1.83) 1.15 (0.97–1.32)
COL3A1 Microarray 1.49 2.427 2.56
Q-rt-PCR 2.03 (1.36–2.70) 5.86 (3.89–7.81) 6.11 (3.46–8.77)
IRX2 Microarray 0.91 0.64 0.43
Q-rt-PCR 0.88 (0.80–0.97) 0.48 (0.44–0.52) 0.47 (0.42–0.53)
IRX3 Microarray 0.95 0.59 0.55
Q-rt-PCR 0.85 (0.75–0.97) 0.43 (0.38–0.48) 0.42 (0.35–0.52)
IRX5 Microarray 0.97 0.64 0.57
Q-rt-PCR 0.94 (0.92–0.97) 0.55 (0.52–0.58) 0.59(0.55–0.64)
Median values of fold change (E2/treatment). Numbers in brackets are min-max values. Fold changes calculated from signal intensity (microarray) and
concentration (Q-rt-PCR). N = 6 for each treatment.
doi:10.1371/journal.pone.0122339.t002
Fig 4. KRT6mRNA expression after estrogen deprivation in MCF-7 cells.MCF-7 cells were grown in
phenol red-free Alpha MEM supplemented with 5% charcoal-stripped FBS for 3 days. Cells grown for 3 days
in presence of 17β-estradiol (10 nM) were used as control. The mRNA expression was measured by Q-rt-
PCR and the relative expression levels of each gene were related to TBP mRNA. The results presented are
mean values with SEM from 3 biological replicates.
doi:10.1371/journal.pone.0122339.g004
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To further analyze the metabolite-specific potency to regulate gene expression, we searched
for genes that were differentially expressed after treatment with 4OHtam and at the same time
more differentially expressed after treatment with 4OHNDtam (rank product analysis, fold
change1.5 for each step and q-value 0.2). These cut-off values resulted in 20 up-regulated
genes and 81 down-regulated genes, that we subjected to PANTHER analysis to evaluate their
function (S1 Fig). We found that the categories developmental processes and signaling, includ-
ing G-protein coupled receptor protein signaling pathway, were over-represented among the
down-regulated genes (fold change 0.05, S7 Table). Genes involved in neurological processes
such as sensory perception were found to be over-represented among the up-regulated genes
(S8 Table). The cancer related category apoptosis was over-represented with both up- and
down-regulated genes, represented by two up-regulated genes (TNS3, EMP1) and five genes
down-regulated (DNASE1L2, CXCR4, Gal-7, FKBP5, SGK1) (Table 3).
Discussion
In this paper, we investigated changes in global gene expression in response to three tamoxifen
metabolites: 4OHtam, 4OHNDtam and NDtam. The main findings are that 4OHNDtam and
4OHtam strongly altered global gene expression in E2 treated MCF-7-cells compared to treat-
ment with estrogen alone. The effects of 4OHNDtam and 4OHtam largely overlapped, with an
overall stronger response for 4OHNDtam. NDtam had nearly no effect. We moreover identi-
fied specific genes that responded selectively to either 4OHNDtam or 4OHtam, providing new
molecular insight into metabolite-specific effects with tamoxifen treatment. Our study, using
physiological metabolite ratios, improves our understanding of how tamoxifen may mediate its
positive and adverse effects in vivo.
Effects of NDtam and tamoxifen have previously been studied in MCF-7 cells. Reddel and
Sutherland [30], using much higher concentrations than those observed in man (7.5–10 μM),
observed that NDtam was much more potent than tamoxifen in inhibiting growth. This inhibi-
tion of cell proliferation was only partially reversed by E2 or not reversed at all. The results may
be due to direct toxic effects of NDtam and not promoted via the influence on the ER. Hawse
et al examined effects of 4OHtam, 4OHNDtam and NDtam in MCF-7cells in an extensive
study, however they did not report on results when NDtam was used as a single drug [15].
Even with high concentrations of NDtam, mimicking that observed in man during steady state
treatment, our microarray analysis clearly demonstrated that NDtam had little impact on glob-
al gene expression in E2-treated MCF-7 cells. This indicates that 4OHtam and 4OHNDtam are
the main contributors to the anti-estrogenic effects of tamoxifen. However, NDtam, as the
major tamoxifen metabolite, may still contribute to toxic effects such as crystalline retinal de-
posits, macular edema, and corneal changes that have been observed previously [31, 32].
In line with others [15, 33], we observed that treatment with 4OHtam and 4OHNDtam re-
sulted in differential gene expression in E2 treated MCF-7 cells when compared to MCF-7 cells
treated with E2 alone. A clear shift in gene expression was seen in the CA (Fig 1) after the treat-
ment with 4OHtam and 4OHNDtam, however the shift was greater for 4OHNDtam than with
4OHtam. The CA showed a shift in gene expression in the same direction for 4OHtam and
4OHNDtam. When comparing the GO of the two metabolite effects separately (Fig 6), we
found that genes in categories related to cancer processes such as intracellular signaling cascade
Fig 5. KRT6mRNA expression after knockdown of SRC-3 in MCF-7 cells. A:Quantification of SRC-3
mRNA expression in MCF-7 cells infected with shRNA targeting SRC-3 (SRC-3 shRNA) and Control shRNA.
B-D:mRNA expression of KRT6A, KRT6B and KRT6C in SRC-3 shRNA- and Control shRNAMCF-7 cells.
The expression level of each gene is relative to TBP mRNA. The results presented are mean values with
SEM from 6 biological replicates.
doi:10.1371/journal.pone.0122339.g005
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were significantly down-regulated. Categories such as cell adhesion were up-regulated by both
metabolites, whereas genes involved in cell cycle were down-regulated. In addition, genes in
the cell motion category were down-regulated by 4OHNDtam, however not significantly by
Fig 6. Functional categorization of differentially expressed genes in MCF-7 cells after treatment with tamoxifen metabolites. PANTHER was used to
search for over-represented categories in the ontology class Biological Process. A significance of microarray analysis (SAM) was applied to search for genes
that were differentially expressed after treatment with the three different tamoxifen metabolites. Genes with q-val 0 and fold change1.5 were selected
from the SAM analysis. A p-value 0.05 was used as inclusion criterion for categories. The reference column at the left of the table displays the percentage
of genes that belongs to a specific category when analyzing the whole human NCBI genome (19,911 genes), e.g. 5% of the 19,911 genes belong to the
“Apoptosis” category. The same principle goes for the other numerical columns, e.g. in the 4OHNDtam vs. E2 column there are 82 up-regulated genes and
9% of these belonged to the “Apoptosis” category. The color intensity scales are based on the statistical significance (-log p-value) of over- and under-
represented PANTHER functional categories. Red illustrates “over-represented category” where more genes than expected were found in a specific
category. Blue color illustrates “under-represented category” where less genes than expected were found. Ref, Reference genes. Arrow up, up-regulated
genes. Arrow down, down-regulated genes.
doi:10.1371/journal.pone.0122339.g006
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Table 3. Genes with differential expression after treatment with 4OHtam andmore differential expression after treatment with 4OHNDtam belong-
ing to biological process category (PANTHER).
Up-regulated Down-regulated
Developmental process VGLL1, BASP1, EMP1, KRT4 KRT6A, CXCR4, TUBA3D, EGR3, EGR2, MGP, KRT17, PRLR, IRX2,
HEY2, SIAH2, OLFM1, KRT6C, IL27RA, TUBA3D, KRT6B
System development BASP1 CXCR4, EGR3, EGR2, PRLR, MGP, IRX2, HEY2, SIAH2, OLFM1,
IL27RA
Nervous system development BASP1 CXCR4, EGR3, EGR2, IRX2, HEY2, SIAH2, OLFM1
Ectoderm development BASP1, EMP1, KRT4 KRT6A, CXCR4, EGR3, EGR2, IRX2, HEY2, SIAH2, OLFM1, KRT6C,
KRT6B
Cellular process TNS3, EMP1, KRT4, INHBB,
CAV1, GABRP
KRT6A, GPR68, RERG, CXCR4, TUBA3D, TGFA, CCBP2, Gal-7,
FXYD4, FKBP5, EGR3, EGR2, GPER, MGP, RAB31, KRT17, PRLR,
CCBP2, SGK1, Gal-7, GEM, PPP2R5A, ANXA8, OLFM1, KRT6C,
IL27RA, TUBA3D, KRT6B, OXTR, PKIB
Cell communication TNS3, INHBB, CAV1, GABRP GPR68, RERG, CXCR4, TGFA, CCBP2, FXYD4, GPER, FKBP5, MGP,
RAB31, PRLR, SGK1, GEM, CCBP2, PPP2R5A, ANXA8, OLFM1,
IL27RA, OXTR, PKIB
Signal transduction TNS3, INHBB, CAV1, GABRP GPR68, RERG, CXCR4, TGFA, CCBP2, FXYD4, GPER, FKBP5, MGP,
RAB31, PRLR, SGK1, GEM, CCBP2, PPP2R5A, ANXA8, OLFM1,
IL27RA, OXTR, PKIB
Intracellular signaling cascade RERG, RAB31, PRLR, FKBP5, SGK1, GEM, PPP2R5A, IL27RA, OXTR,
PKIB
Apoptosis TNS3, EMP1 DNASE1L2, CXCR4, Gal-7, FKBP5, SGK1, Gal-7
Cell surface receptor linked signal
transduction




CXCR4, TGFA, CCBP2, PRLR, CCBP2, IL27RA
G-protein coupled receptor
protein signaling pathway
CAV1 RERG, GPR68, CXCR4, CCBP2, GPER, CCBP2, GEM, OXTR
Reproduction STARD5, OXTR
Gamete generation STARD5, OXTR
Female gamete generation STARD5, OXTR
Metabolic process HSD17B11, GALNT12, TNS3,
TGM2, DIO1, SPINK4, CAV1
DNASE1L2, SERPINA3, NXNL2, EGR3, EGR2, FKBP5, STARD5,
LRRFIP2, SGK1, IRX2, KLK5, HEY2, PPP2R5A, ISG20, ANXA8, SIAH2,
C5orf4, NAB2, SOX3, SOX9, SERPINA5, NT5DC3, ALDH3B2, ABCA12
Primary metabolic process GALNT12, TNS3, TGM2,
SPINK4, CAV1
DNASE1L2, SERPINA3, EGR3, EGR2, FKBP5, STARD5, LRRFIP2,
SGK1, IRX2, KLK5, HEY2, PPP2R5A, ISG20, ANXA8, SIAH2, C5orf4,
NAB2, SOX3, SOX9, SERPINA5, NT5DC3, ABCA12
Lipid metabolic process TNS3, CAV1 STARD5, ANXA8, C5orf4, ABCA12
Steroid metabolic process C5orf4, ABCA12
Cholesterol metabolic process C5orf4, ABCA12
Nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
DNASE1L2, EGR3, EGR2, LRRFIP2, IRX2, HEY2, ISG20, NAB2, SOX3,
SOX9, NT5DC3
DNA metabolic process DNASE1L2
DNA catabolic process DNASE1L2
System process BASP1, SCNN1A, EMP1,
GABRP, EYA2
RERG, FKBP5, OXTR
Neurological system process BASP1, SCNN1A, EMP1,
GABRP, EYA2
RERG, FKBP5, OXTR
Sensory perception SCNN1A, EYA2 OXTR
Sensory perception of chemical
stimulus
SCNN1A
Sensory perception of taste SCNN1A
Regulation of biological process SCNN1A
Regulation of vasoconstriction SCNN1A
doi:10.1371/journal.pone.0122339.t003
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4OHtam. Further, we found an up-regulating effect on genes related to antigen processing and
presentation, a pathway associated with the emerging hallmark of cancer [34]: evasion of im-
mune surveillance. This up-regulation was observed after treatment with 4OHNDtam, but not
with 4OHtam. It is believed that cancer cells that are weakly immunogenic, and therefore
harder to identify by the immune system, are the cells which eventually will form a solid tumor
[34]. There are several theories surrounding how the weakly immunogenic cancer cells are able
to avoid being recognized by the immune system, and how the cells became weakly immuno-
genic. For breast cancer cells this may involve down-regulation of components of the major
histocompatibility complex [35] or, as recently proposed, by releasing proteins associated with
MHC-I through exosomes [36]. Our results show an up-regulation of genes associated with an-
tigen processing and presentation of peptide or polysaccharide antigens via MHC class II. This
might represent an effect of 4OHNDtam that counteracts the evasion of immune-surveillance.
However, further studies are needed to explore this hypothesis.
The differential expression observed was generally stronger during 4OHNDtam treatment.
These results are in line with earlier studies suggesting that 4OHNDtam is the main compound
promoting the clinical effects of tamoxifen treatment [2, 37]. We further studied the stronger
regulation observed by treatment with 4OHNDtam by selecting genes that were regulated by
both metabolites, but more strongly by 4OHNDtam. In the PANTHER analysis performed on
these genes (S1 Fig, Table 3), the apoptosis category was of particular interest. There was an
over-representation of both up-regulated genes and down-regulated genes in this category. On
closer inspection the up-regulated genes (TNS3, EMP1) were positive regulators of apoptosis
[38] and 4 out of 5 down-regulated genes (CXCR4, Gal-7, FKBP5, SGK1) were negative regula-
tors of apoptosis [39–42].
An interesting finding is the strong down-regulation by 4OHNDtam of genes expressing
the different keratin 6 isoforms (KRT6a, KRT6b and KRT6c). KRT6a was the most down-regu-
lated gene in our analysis (9.1–fold), and the effect on this gene was weaker after treatment
with 4OHtam (1.8-fold decrease). The two-step validation by removal of the ligand (E2) (estro-
gen deprivation) (Fig 4) and knockdown of an important ER-coactivator (SRC-3/AIB1) (Fig 5)
also suggest that the KRT6s are positively regulated by ER. It should be noted that SRC-3/AIB1
is overexpressed in 31–64% of human breast tumors [43, 44], and has been shown to increase
the agonist properties of tamoxifen [45].
The keratins, also called cytokeratins (CKs), belong to the intermediate filament proteins
that create an insoluble dense meshwork through the cytoplasm giving structural support to
the epithelial cell. Recently, however, it was shown that CKs play a more active role in various
internal cellular survival processes (e.g. proliferation and apoptosis). These proteins may un-
dergo phosphorylation and are also part of the bridging contact between the epithelial cell and
its microenvironment [46]. CK6a is the dominant isoform in the mammary gland [47] and is
up-regulated in the proliferative basal cells in healing wound edges of the skin, indicating that
this CK is involved in cellular proliferation and migration [48]. Knockout of CK6 is associated
with reduced proliferation in the murine mammary epithelium [47]. These genes are highly
up-regulated in the basaloid molecular subtype of breast cancer demonstrated by Perou and
Sorlie [49]. Interestingly, co-expression of CK 5/6 in ER positive breast cancer tumors seems to
define a subset of patients with a more adverse prognosis [50, 51]. Therefore, the down-regula-
tion of CK6 by 4OHNDtam should be further explored in appropriate designed `bench-to-
bed`studies since it may represent a new insight in understanding of the anti-cancer action of
this active tamoxifen metabolite in ER positive breast tumors.
The present study has limitations. The standard tamoxifen metabolites used were not pure
z-isomers. In the clinical situation both isomers are present although the z-isomers dominate
[52]. Furthermore some isomerization may occur in the cultures during the study. Accordingly,
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Katzenellenbogen et al observed a facile geometric isomerization of anti-estrogens which hap-
pened in tissue cultures as well as cell free medium [53]. They found that the MCF-7 cells
mainly accumulated the trans-isomer and at the nuclear ER mainly the trans-isomer was locat-
ed. Further limitations of the study are that we studied the effects of the metabolites only at one
given concentration. It must also be taken into account that the concentration of 4OHNDtam
was 10 times higher than that of 4OHtam in order to mimic the clinical situation, so the stron-
ger regulation seen by 4OHNDtam might be a reflection of the concentration differences.
Conclusions
Conclusively, the global gene expression changes caused by 4OHNDtam treatment of estrogen
treated MCF-7 cells are stronger than those of 4OHtam when using concentrations that mimic
the clinical situation. NDtam caused only minimal effects. Genes encoding CytoKeratin 6 were
highly down-regulated by 4OHNDtam, as well as after E2 deprivation and knockdown of SRC-
3/AIB1, indicating an estrogen receptor-dependent regulation. Further studies are warranted
to elucidate possible clinical applications of this finding.
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